07:00 , Apr 28, 2014 |  BC Week In Review  |  Clinical News

Isomerase Therapeutics, NeuroVive preclinical data

In a mouse model of HBV infection, once-daily 100 mg/kg NVP018 led to a 1.2-1.5 log reduction in HBV DNA levels over 14 days. Data were presented at the European Association for the Study of...
01:24 , Jun 29, 2013 |  BC Extra  |  Politics & Policy

BioIndustry Association names Hodgkin chairman

The U.K.'s BioIndustry Association appointed Edward Hodgkin as chairman, effective Oct. 30. He succeeds Tim Edwards, who will remain a director. Hodgkin is a partner at Syncona Partners and was CEO of Biotica Technology Ltd....
07:00 , Jun 17, 2013 |  BC Week In Review  |  Company News

Isomerase Therapeutics, NeuroVive deal

NeuroVive partnered with Isomerase to develop and commercialize preclinical cyclophilin inhibitors that NeuroVive acquired from Biotica Technology Ltd. (Cambridge, U.K.). The deal will focus on cellular protection for traumatic brain injury and heart attack and...
07:00 , Mar 18, 2013 |  BC Week In Review  |  Company News

Biotica, NeuroVive deal

NeuroVive acquired a portfolio of cyclophilin inhibitors, technology platform assets and related IP from Biotica. NeuroVive said it plans to use the technology and IP to develop next-generation versions of its mitochondrial products for cardiovascular...
08:00 , Mar 5, 2012 |  BioCentury  |  Product Development

Dynamic duo

Novartis AG 's deal with Enanta Pharmaceuticals Inc. gives the pharma two angles for targeting HCV that act directly and indirectly against the non-structural protein 5A. The combination of Enanta's direct inhibitor with the pharma's...
07:00 , Sep 19, 2011 |  BC Week In Review  |  Company News

Biotica, Buck Institute for Research on Aging deal

Biotica and the not-for-profit institute partnered to discover and develop therapies using rapamycin analogs and other polyketides to treat age-related diseases, including Alzheimer's disease (AD), Parkinson's disease (PD) and Huntington's disease (HD). Under the three-year...
07:00 , Aug 8, 2011 |  BC Week In Review  |  Company News

Biotica, Pfizer deal

Biotica said Pfizer terminated a 2006 deal and returned full rights to the rapamycin analog program. Biotica said Pfizer made the decision as part of a portfolio review process. Biotica will continue development of undisclosed...
07:00 , Jul 19, 2010 |  BC Week In Review  |  Company News

Biotica, Bristol-Myers deal

Biotica acquired a type II polyketide chemical library and IP related to a bioengineering technique from Bristol-Myers. Biotica said the deal strengthens its polyketide engineering platform and the IP complements its lead optimization and heterologous...
08:00 , Jan 19, 2009 |  BC Week In Review  |  Company News

Biotica, GlaxoSmithKline deal

Biotica and GlaxoSmithKline partnered to discover, develop and commercialize erythromycin-based macrolides to treat inflammatory diseases. Under the three-year deal, Biotica will use its polyketide bioengineering technology to produce compounds. GlaxoSmithKline is responsible for optimization, development...
02:22 , Jan 13, 2009 |  BC Extra  |  Company News

Biotica, GSK to discover macrolides for inflammation

Biotica (Cambridge, U.K.) and GlaxoSmithKline (LSE:GSK; NYSE:GSK) partnered to discover, develop and commercialize erythromycin-based macrolides to treat inflammatory diseases. Under the three-year deal, Biotica will use its polyketide bioengineering technology to produce compounds. GSK is...